Showing 1 - 8 of 8
Persistent link: https://www.econbiz.de/10001799719
The aim of this essay is to give an overview about recent developments of the government innovation funds of Sweden and … Finland. In order to discover recent developments basic knowledge regarding innovation funds, funding structures and … the COVID-19 pandemic. Both Sweden and Finland had to really push forward innovation with financial support and political …
Persistent link: https://www.econbiz.de/10013171497
We analyze the frequency and nature by which new firms are acquired by established businesses. Acquisitions are often considered to reflect a technology transfer process and to also constitute one way in which a “symbiosis” between new technology-based firms (NTBFs) and established...
Persistent link: https://www.econbiz.de/10010945043
This study investigates the determinants of R&D expenditures in the Swedish pharmaceutical industry from the 1960s to the mid 1990s. Various proxies for the rate of return of R&D (e.g. expected profit, sales and R&D productivity) as well as the availability of internal funding (proxied by past...
Persistent link: https://www.econbiz.de/10005077278
, focusing on the relation between institutions and innovation practices and taking into account the diversity of actors …
Persistent link: https://www.econbiz.de/10010818687
This study investigates the determinants of R&D expenditures in the Swedish pharmaceutical industry from the 1960s to the mid 1990s. Various proxies for the rate of return of R&D (e.g. expected profit, sales and R&D productivity) as well as the availability of internal funding (proxied by past...
Persistent link: https://www.econbiz.de/10008764489
It is widely accepted that firms in peripheral regions benefit to a lesser extent from local knowledge spillovers than firms located in agglomerations or industrial clusters. This paper investigates the extent to which innovative firms in peripheral regions compensate for the lack of access to...
Persistent link: https://www.econbiz.de/10011105519
We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical … expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is … the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …
Persistent link: https://www.econbiz.de/10010569681